Danish Commercial Services Stock News

Alm. Brand (CPSE:ALMB) has drawn attention after extending its collaboration with Ondo InsurTech’s LeakBot. The insurer plans to offer the leak detection device to up to 160,000 homeowners across its Danish insurance brands. See our latest analysis for Alm. Brand. The expanded LeakBot rollout and recent AGM decisions come after a weaker short term patch, with a 90 day share price return of 16.44% decline and year to date share price return of 17.74% decline, set against a 1 year total...

TORM plc ( CPH:TRMD A ) shareholders will have a reason to smile today, with the analysts making substantial upgrades...

Recent share performance and business snapshot Novo Nordisk (CPSE:NOVO B) has been under pressure, with the share price showing a 1 day decline of about 1% and negative returns over the past week, month and past 3 months. Despite this weaker recent performance, the company reports annual revenue of DKK 309.1b and net income of DKK 102.4b. Most of this comes from its Diabetes and Obesity Care segment, supported by a smaller Rare Disease business. See our latest analysis for Novo Nordisk. At...

As European markets experience a rally, with the STOXX Europe 600 Index climbing over 3% amid easing geopolitical tensions, investors are increasingly focused on identifying value opportunities within this buoyant environment. In such conditions, a good stock is often characterized by its potential to be undervalued relative to intrinsic estimates, offering a promising avenue for those seeking to capitalize on market optimism while maintaining an eye toward long-term fundamentals.

Readers hoping to buy Scandinavian Tobacco Group A/S ( CPH:STG ) for its dividend will need to make their move shortly...

Capital reduction and what it means for Pandora shareholders Pandora (CPSE:PNDORA) has confirmed a reduction in its share capital after cancelling 4,000,000 treasury shares of DKK 1, an action now completed following approval at the recent Annual General Meeting. This capital reduction, registered with the Danish Business Authority after a 4 week notification period without objections, trims the number of shares outstanding and may influence how investors view Pandora’s capital structure and...

CK Hutchison has taken A.P. Møller - Mærsk to arbitration in London over Panama port assets after APM Terminals was appointed interim operator, adding legal complexity to an already politically sensitive dispute involving Panama, the US and China. At the same time, Maersk is confronting fresh uncertainty in the Strait of Hormuz as Iran seeks cryptocurrency toll payments during a temporary ceasefire, underlining how geopolitical and regulatory shifts can directly affect the company’s global...

As European markets navigate the complexities of Middle East tensions and energy market volatility, the pan-European STOXX Europe 600 Index has shown resilience, ending the week up 3.92% in local currency terms. This positive sentiment is supported by hopes for a shorter-lived conflict and is reflected in gains across major stock indexes like Germany's DAX and Italy's FTSE MIB. In this environment, identifying promising stocks involves looking for companies with strong fundamentals that can...

Why FLSmidth (CPSE:FLS) is in focus right now FLSmidth (CPSE:FLS) has just completed the sale of its former corporate headquarters in Valby, Denmark, a previously flagged transaction that brings in net cash proceeds and an accounting gain in Q1 2026. See our latest analysis for FLSmidth. The DKK504.5 share price has climbed 4.4% over the last day and 8.9% over 90 days. The 1 year total shareholder return of 86.6% points to strong longer term momentum, even after a recent 4.4% 1 month share...

Zealand Pharma (CPSE:ZEAL) recently announced a new research hub in Cambridge, Massachusetts. This facility will become its primary U.S. base and will focus on AI-driven drug discovery, advanced automation, and new therapeutic modalities. See our latest analysis for Zealand Pharma. The share price is DKK298.0 after a 1-day share price return of 1.02% and a 7-day share price return of 3.47%. However, the 30-day and year-to-date share price returns of -19.28% and -35.23% suggest recent momentum...

In late March 2026, Vestas Wind Systems announced a series of new wind turbine orders across Germany, France, the UK and the USA, alongside long-term service agreements and deliveries stretching from 2026 to 2028, and separately revealed plans for a more than €250 million nacelle and hub factory in Scotland targeting its V236-15.0 MW offshore turbines. Taken together, the fresh onshore order intake and the conditional Scottish offshore factory plan underline how Vestas is tying near-term...

Wondering whether Ørsted at DKK158.45 is starting to look like value, or still priced for high expectations? This article breaks down what the current share price may be implying. The stock has returned 9.2% over the last 7 days and 5.1% over the past month, yet over 1 year it is down 7.6% and over 5 years it is down 71.1%. This raises questions about how investors are reassessing both risk and potential. Recent attention on Ørsted has focused on its position in renewable energy and how...

Investors may be wondering whether Bavarian Nordic is attractively priced at its current level, or if the recent run has already incorporated most of the value. The stock last closed at kr197.25, with returns of 3.8% over 7 days, 2.4% over 30 days, 2.3% year to date, 30.7% over 1 year, 1.0% over 3 years, and a 31.8% decline over 5 years. Recent news coverage has focused on Bavarian Nordic's role in vaccines and biopharmaceuticals. This has kept attention on the company as investors reassess...

As European markets navigate heightened uncertainty due to geopolitical tensions and soaring energy costs, the pan-European STOXX Europe 600 Index has seen a notable decline of 3.79%. Amidst these challenges, investors may find opportunities in stocks that appear undervalued based on their intrinsic value, offering potential for growth when market conditions stabilize.

Zealand Pharma (CPSE:ZEAL) is setting up a major U.S. research hub in Cambridge, Massachusetts, focused on AI-driven drug discovery and automation. The new site will support work on hybrid therapies, including antibody peptide conjugates and siRNAs, alongside the company’s peptide heritage. The expansion is intended to plug Zealand Pharma directly into the Boston life sciences cluster, with implications for scientific capabilities and hiring. For investors tracking Zealand Pharma at a share...

Lu AF28996 data puts H. Lundbeck (CPSE:HLUN B) pipeline in focus Fresh Phase 1b data for Lundbeck's Lu AF28996 in advanced Parkinson's disease, combined with new insights on multiple system atrophy, has pushed the drugmaker's research pipeline and long term neurology focus back into the spotlight. See our latest analysis for H. Lundbeck. At a share price of DKK37.64, Lundbeck has a 90 day share price return of a 12.47% decline and a 1 year total shareholder return of a 0.50% decline, so...

Lundbeck’s new clinical data on Lu AF28996 and the amlenetug program at the 2026 AD/PD conference has refocused attention on Genmab (CPSE:GMAB), given its collaboration role in developing amlenetug. See our latest analysis for Genmab. At a share price of DKK1,655.5, Genmab has a 1 day share price return of 1.13%, following a 30 day share price return decline of 10.68% and a 90 day share price return decline of 22.02%. The 1 year total shareholder return of 24.94% contrasts with weaker 3 and 5...

Bylaw changes and capital structure moves grab investor attention Embla Medical hf (CPSE:EMBLA) has drawn fresh interest after its 2026 Annual General Meeting approved share capital reductions, renewed board authorizations for future capital increases, and set out conditions for new share buyback and employee option programs. See our latest analysis for Embla Medical hf. Despite the AGM activity around buybacks and share capital, Embla Medical hf's share price has eased in recent months, with...

Bavarian Nordic A/S recently reported full-year 2025 results, with sales rising to DKK 6,243.96 million and net income reaching DKK 1,375.38 million, alongside higher earnings per share from continuing operations. A day earlier, the company expanded its partnership with Serum Institute of India to transfer chikungunya vaccine manufacturing and explore further co-development, potentially broadening access in low- and middle-income countries. Next, we’ll assess how the chikungunya tech...

Ørsted (CPSE:ORSTED) has proposed the election of three new board members at its annual general meeting scheduled for April 2026. The nominees are Karen Boesen, Karl Johnny Hersvik, and Samuel Leupold, each bringing experience in energy and renewables. Two current board members are not seeking re election, which would reshape the composition of Ørsted's board if the proposals are approved. For shareholders, these board changes come with Ørsted's share price at DKK144.0 and a mixed return...

Why Coloplast’s CEO transition is in focus Coloplast (CPSE:COLO B) is back on investors’ radar after the board appointed Gavin Wood as President and CEO, effective 1 May 2026, following a year under interim chief Lars Rasmussen. Wood arrives from senior roles at Johnson & Johnson MedTech EMEA and previous leadership positions at Mölnlycke and Ethicon, raising questions about how his background could shape Coloplast’s future direction and its healthcare portfolio. See our latest analysis for...

Københavns Lufthavne (CPSE:KBHL) has wrapped up FY 2025 with Q4 revenue of DKK 1,368 million and basic EPS of DKK 32.95, while trailing twelve month figures sit at DKK 5.5 billion in revenue and EPS of DKK 158.00, reflecting earnings growth of 19.6% over the period. The company has seen quarterly revenue move from DKK 1,245 million and EPS of DKK 24.98 in Q4 2024 to DKK 1,368 million and EPS of DKK 32.95 in Q4 2025, with margins stepping up from 20% to 22%. This puts profitability at the...

Earlier this month, Zealand Pharma reported positive topline Phase 2 ZUPREME-1 results showing petrelintide achieved statistically significant, clinically meaningful weight loss with tolerability similar to placebo in people living with overweight and obesity. The data suggest petrelintide’s once-weekly amylin-based profile could offer a differentiated, potentially more tolerable alternative to existing peptide weight-loss therapies, reinforcing Zealand’s obesity franchise with Roche. We’ll...

If you are wondering whether GN Store Nord's current share price reflects its true worth, you are not alone. This article is built to help you make sense of what the market is pricing in. GN Store Nord shares last closed at DKK 87.08, with returns of 6.2% decline over 7 days, 11.8% decline over 30 days, 20.8% decline year to date, 26.3% decline over 1 year, 39.0% decline over 3 years and 81.8% decline over 5 years. These moves may have shifted how investors think about both risk and...